<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57046">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01936233</url>
  </required_header>
  <id_info>
    <org_study_id>LC-ASPIRIN</org_study_id>
    <secondary_id>ASPIRIN-13-08</secondary_id>
    <nct_id>NCT01936233</nct_id>
  </id_info>
  <brief_title>Clinical Study of Antiviral and Aspirin Treatment in Liver Cancer After Radical Surgery</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sustained chronic  hepatitis B virus inflammation is a major cause of liver cancer
      occurrence and development. Antiviral treatment can block the persistent infection. Aspirin
      can inhibit platelet function and  CD8 + T cell mediated liver cell necrosis and
      inflammation. Aspirin also can inhibit liver cancer cells  metastasis through inhibit COX2.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>recurrence free survival</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse  events</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Recurrence</condition>
  <arm_group>
    <arm_group_label>Aspirin AND Lamivudine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lamivudine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Aspirin 0.1 QD po</description>
    <arm_group_label>Aspirin AND Lamivudine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>LAminvudine 0.1 QD po</description>
    <arm_group_label>Aspirin AND Lamivudine</arm_group_label>
    <arm_group_label>Lamivudine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hepatocellular carcinoma confirmed with pathology or identified with radiological
             images with typical features

          -  Age ≥ 18 years and ≤ 75 years

          -  At least one tumor nodule with one uni-dimension of ≥ 2 cm

          -  Child-Pugh Class A or B

          -  HBV-DNA&gt;10^4

          -  Total bilirubin ≤ 1.5 x upper limit of normal

          -  ALT and AST ≤ 2.0 x the upper limit of normal

          -  PT-INR&lt;2.3,PTT &lt; 1.5 x upper limit of normal

          -  Serum creatinine ≤ 1.5x upper limit of normal

          -  Peripheral white blood cell count of or more than 3×10(9)/L

          -  Peripheral platelet of or more than 50×10(9)/L

          -  Expected survival time not less than 3 months

          -  ECOG score 0-2

        Exclusion Criteria:

          -  Tumor thrombi in main branch of portal vein

          -  Tumor involvement more than 70% of whole liver

          -  With extrahepatic metastasis

          -  Prior systemic chemotherapy or chemoembolization

          -  Congestive heart failure &gt; NYHA class 2

          -  History of HIV infection

          -  Active clinically serious infections (&gt; 2 NCI-CTC Version 3.0)

          -  Recurrence of HCC after liver transplantation

          -  Pregnant or breast-feeding

          -  Substance abuse, medical, psychological or social conditions that may interfere with
             the patient's participation in this study

          -  Known or suspected allergy to any agent given in association with this trial

          -  Patients unable to swallow oral medication

          -  Inclined to thrombosis

          -  Inclined to hemorrhage or active hemorrhage with 1 month
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zheng-Gang Ren, Ph.D</last_name>
    <phone>0086-021-64041990</phone>
    <phone_ext>2149</phone_ext>
    <email>ren.zhenggang@zs-hospital.sh.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lan Zhang, MD</last_name>
    <phone>0086-021-64041990</phone>
    <phone_ext>2971</phone_ext>
    <email>zhang.lan@zs-hospital.sh.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Liver Cancer Institute</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zheng-Gang Ren, Ph.D</last_name>
      <phone>0086-021-64041990</phone>
      <phone_ext>2149</phone_ext>
      <email>ren.zhenggang@zs-hospital.sh.cn</email>
    </contact>
    <contact_backup>
      <last_name>Lan Zhang, Master</last_name>
      <phone>0086-021-64041990</phone>
      <phone_ext>2971</phone_ext>
      <email>zhang.lan@zs-hospital.sh.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>September 5, 2013</lastchanged_date>
  <firstreceived_date>September 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zheng-Gang Ren</investigator_full_name>
    <investigator_title>chief of departement</investigator_title>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>Aspirin</keyword>
  <keyword>antiviral treatment</keyword>
  <keyword>recurrence free survival</keyword>
  <keyword>radical therapy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Antiviral Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
